ClinicalTrials.gg
CompletedNCT06475872Updated Jun 27, 2024

Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects

A Phase 1 interventional study of Crecheck Tablet 2.5 mg and Crestor Tablet 5 mg in Primary Hypercholesterolemia and Combined Hyperlipidemia, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2023, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
52nd of 57
36 · median 203
Started
2023
the only one that year
Phase 1
5 of 59
none open now
Registered
56th of 59
by date
Lead sponsor
2 of 59
Hanlim Pharm. Co., Ltd.

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 52nd largest by enrollment of the 57 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 1, and was the 56th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

This clinical trial is an open, randomized, 2-group, 2-period, fasting, single-dose, crossover study to evaluate the bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" of Hanlim Pharm. Co., Ltd. and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" of AstraZeneca Korea Co., Ltd. in healthy adult subjects.

Read the detailed description

This study is to compare and evaluate the safety and pharmacokinetic characteristics of Hanlim Pharm. Co., Ltd.'s "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" as the test drug and AstraZeneca Korea Co., Ltd.'s "Crestor Tablet 5 mg (Rosuvastatin Calcium)" as the reference drug in healthy adults.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Combined Hyperlipidemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals aged 19 years or older at the time of screening
  2. Individuals with no congenital or chronic diseases and no pathological symptoms or findings based on medical examinations (such as EEG, , chest and gastric endoscopy, or gastrointestinal radiology tests, if necessary)
  3. Individuals deemed suitable for the study based on screening tests (e.g., hematology, blood chemistry, serology, and urinalysis) as determined by the principal investigator (or a designated sub-investigator)
  4. Individuals with a (BMI) between 18.0 and 30.0 (BMI calculation: weight (kg) / height (m)²)
  5. Individuals who have received and understood a thorough explanation of the study's purpose, content, drug characteristics, and potential adverse events, and have voluntarily decided to participate and agreed in writing to comply with the study requirements during the trial period
  6. Individuals who agree to use medically recognized methods* (excluding hormonal contraceptives) to avoid pregnancy from the first administration of the investigational drug until one week after the last administration * Medically recognized contraceptive methods: intrauterine devices (IUD, IUS), vasectomy, tubal ligation, and combined barrier methods (male condoms, female condoms, cervical caps, diaphragms, sponges, etc.), or if using spermicides, combined use of two or more barrier methods

Exclusion criteria

Exclusion Criteria:

  1. Individuals who have taken enzyme-inducing or inhibiting drugs such as barbiturates within 30 days before the start of the study (first dosing day) or medications that might interfere with the study within 10 days before the start of the study (first dosing day)
  2. Individuals who have engaged in excessive alcohol consumption within one month before the start of the study (first dosing day)

    • For men, more than an average of 21 drinks per week
    • For women, more than an average of 14 drinks per week (One drink: 45 mL of distilled spirits or 360 mL of beer or 150 mL of wine)
  3. Individuals who have participated in clinical trials (including bioequivalence studies) and received drugs within six months before the start of the study (first dosing day)
  4. Individuals who have donated whole blood within 8 weeks or donated blood components within 2 weeks before the start of the study (first dosing day)
  5. Individuals with a history of gastrointestinal surgery that may affect drug absorption
  6. Patients with the following conditions:

    • to the components of this drug
    • Active liver disease, including unexplained persistent elevations in serum transaminases or serum transaminase levels exceeding three times the
    • Myopathy
    • Concurrent use of cyclosporine
    • Severe renal impairment ( (CLcr) \< 30 mL/min)
    • Pregnant or lactating women, and women of not using adequate methods
    • Patients prone to myopathy/rhabdomyolysis ( when administered at a 40 mg dose of this drug)
    • Moderate renal impairment (creatinine clearance \< 60 mL/min)
    • Hypothyroidism
    • A history or family history of hereditary muscle disorders
    • A history of muscle toxicity with other HMG-CoA reductase inhibitors or fibrates
    • Alcoholism
    • Situations where plasma concentrations may increase
    • Asian patients
    • Concurrent use of fibrates
    • Genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, since this product contains lactose
  7. Individuals with a history of mental illness
  8. Individuals deemed unsuitable for this clinical trial for reasons other than the above inclusion/exclusion criteria by the principal investigator (or a designated sub-investigator)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Crecheck Tab

    On the day of the visit, take 2 tablets of the test drug orally with 150 mL of water around 8 am.

    Drug: Crecheck Tablet 2.5 mg

  • Active comparator
    Comparator

    On the day of the visit, take 1 tablet of the comparator drug orally with 150 mL of water around 8 am.

    Drug: Crestor Tablet 5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Concentration of rosuvastatin in plasma

    Time frame: 48 hours

  2. Peak Plasma Concentration (Cmax)

    Concentration of rosuvastatin in plasma

    Time frame: 48 hours

Secondary outcomes

  1. Time to Maximum Plasma Concentration (Tmax)

    Concentration of rosuvastatin in plasma

    Time frame: 48 hours

  2. Half Life (t1/2)

    Concentration of rosuvastatin in plasma

    Time frame: 48 hours

  3. AUC∞

    Concentration of rosuvastatin in plasma

    Time frame: 48 hours

  4. AUCt/AUC∞(%)

    Concentration of rosuvastatin in plasma

    Time frame: 48 hours

  5. Dissolution pattern by comparative dissolution test of Rosuvastatin

    Time frame: 48 hours

07

Study locations

1 site
  • Seok Gyeong Medical Foundation Central Hospital
    Gyeonggi-do, 15079, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2023, 0 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 26, 2024
StartActual
Nov 20, 2023
Primary completionActual
Dec 7, 2023
CompletionActual
Dec 7, 2023
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06475872
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Nov 20, 2023
Primary completion
Dec 7, 2023
Completion
Dec 7, 2023
Last update
Jun 27, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion